Dickens, Colin
Ramesh, Ahalya
Adanlawo, Temiloluwa
DeBaun, Michael R.
Article History
Received: 8 November 2023
Accepted: 16 November 2023
First Online: 9 December 2023
Competing interests
: M.R. DeBaun and his institution sponsored two externally funded research investigator-initiated projects. Global Blood Therapeutics (GBT) provided funding for the cost of the clinical studies. GBT was not a co-sponsor of either study. Dr. DeBaun did not receive any compensation for the conduct of these two investigator-initiated observational studies. Dr. DeBaun was a medical advisor in developing the CTX001 Early Economic Model. Dr. DeBaun provided medical input on the economic model as part of an expert reference group for the Vertex/CRISPR CTX001 Early Economic Model in 2020. Dr. DeBaun consulted for the Forma Pharmaceutical company about sickle cell disease in 2021 and 2022. Dr. DeBaun is on the steering committee for a Novartis-sponsored phase II trial to prevent priapism in men with sickle cell disease. All other authors declare no potential conflict of interest.
: Patient consent was not required for this review article.